Event and Webinar

TELUS Health Annual Conference 2024: How AI is reshaping the benefits landscape

Generative artificial intelligence (AI) is a "transformative milestone" that will change our world...
Article

TELUS Health Annual Conference 2024: Drug trends and healthcare transformations

Diabetes, depression, attention deficit hyperactivity disorder (ADHD) and cystic fibrosis are among...
Event and Webinar

TELUS Health Annual Conference 2024

Presentations from April 23 and 30, 2024: Drug data trends and healthcare transformations Vicky...
Report

What private plans need to know about Canada’s pipeline in 2024

In its 2024 Drug Pipeline report, TELUS Health draws attention to 12 new drugs due to their...
Article

The road ahead for pharmacogenomic testing

Pharmacogenomic (PGx) testing may have the potential to revolutionize prescription drug use in...
Article

Revitalizing health connectivity through AI

In a groundbreaking collaboration, TELUS Health and Clinia have revealed an exclusive strategic...
Report

2023 Category Watch: A closer look at disruption

TELUS Health’s 2023 Category Watch closely examines disruption in the drug categories of diabetes,...
Article

Building a DE&I benefits tool kit

The workplaces of today are certainly diverse: they are a mix of employees with different racial...
Article

Where coverage falls short plus other findings from the 2023 Benefits Canada Healthcare Survey

Half of plan members (51 per cent) reported that the coverage level of at least one of their health...
Article

Getting value from private payor drug plans: Considering more than just costs

Following up on our Budget Impact Analysis (BIA) guidance document, TELUS Health has published...
Report

Your copy awaits: the 2023 Drug Data Trends & National Benchmarks report

At a high level, growth in spending by private drug plans was moderate for the third consecutive...
Article

TELUS Health conference 2023: Exploring the value of real-world evidence

At the TELUS Health Annual Conference on May 3, 2023, a panel of industry experts shared their...
Article

TELUS Health Conference: Understanding the mental health of tomorrow’s leaders

After three years of a global pandemic, the workplace has undergone a collective reset of mental...
Article

TELUS Health conference 2023: A deeper dive into drug utilization

Diabetes, asthma, depression and attention deficit hyperactivity disorder (ADHD)—these categories...
Article

TELUS Health conference 2023: What you need to know about drug data trends

The key drivers of change in spending by private drug plans in 2022 can be boiled down to two...
Article

TELUS Health Annual Conference 2023

Presentations from April 26 and May 3, 2023: Retrospective 2022: Drug data trends and national...
Article

How early mental health diagnoses can improve employees’ wellbeing

Many organizations have risen to the challenge when it comes to mental health. They understand the...
Article

A sneak peek at TELUS Health Annual Conference 2023

For the 19th consecutive year, TELUS Health is looking forward to welcoming a record number of...
Article

What private plans can expect in 2023 from Canada’s drug pipeline

Developments in the diabetes category—the second largest category by eligible amount in 2022—will...
Article

5 tools every plan sponsor should consider to cap benefits costs

The future of private drug insurance can be friendly – as long as plan sponsors take action in...
Article

Medication adherence: how to help employees stay on track and save your bottom line

How confident are you that your employees are taking the prescribed medications your plan pays for?...
Article

Top 5 health benefits trends of 2023

If there’s any silver lining to the pandemic then it has to be the modernization of benefit plans...
Article

Mental health in the workplace - a prime focus for employers

Fostering a workplace where employees’ mental health is a priority is suddenly on everyone’s radar....
Article

It takes a village to improve mental health: How employers can contribute to employee well-being.

Supporting employee mental health and well-being is clearly the right thing to do – but it’s also a...
Article

What you need to know about drug data trends in 2022.

For the second year in a row, the pandemic has resulted in fewer plan members making claims for...
Event and Webinar

TELUS Health Annual Conference 2022

Presentations from May 10 & 17, 2022: Retrospective 2021: Data trends and national benchmarks.
Event and Webinar

From adherence to delayed diagnoses, what you need to know about medication use

Would it be better for patients to take more of a medication that may end up costing private drug...
Report

Don’t miss it: The 2022 Drug Data Trends & National Benchmarks report.

Year two of the COVID-19 pandemic saw the continuation of lower rates of prescribing for...
eBook

Working parents in crisis: How employers can better support parents in the workplace

This article was originally published in Benefits and Pensions Monitor. While parents in the...
eBook

From wellness to wellbeing: Why benefits plans need to evolve

Employers understand the need to invest in a healthy workforce, and employees increasingly look to...
Article

What’s your plan to help employees manage chronic conditions?

As Canada’s healthcare system strained and stretched to keep up with the shifting demands of the...
Report

2022 category watch: Impact of the pandemic

TELUS Health’s 2022 Category Watch examines the impact of the COVID-19 pandemic on drug utilization...
Article

Employers bracing for rising cancer claims

For the past two years, discussions around employee health have focused on mental wellness and...
Article

What new drugs are poised to have the biggest impact on plan costs?

The TELUS Health 2022 Drug Pipeline report looks at approved and likely soon-to-be-approved...
Article

Disability management post-COVID: What employers should know

Across the country, employers are working on their post-pandemic planning. In addition to setting...
Article

The private payer’s perspective: Drug trends

Panel discussion from the 20th Annual Market Access Summit. As the COVID-19 pandemic continues to...
Article

Diabetes and Canadian employers

November is Diabetes Awareness Month in Canada. Like many chronic conditions, diabetes has taken a...
Article

Mental health, virtual care rise to surface: Highlights from the 2021 Benefits Canada Healthcare Survey

Employee health has declined over the past year, while the utilization of employee assistance...
Article

Can technology create great plan member experiences?

Managing group health benefits costs, digitizing benefits delivery and data insights are key areas...
Article

Supporting caregiver employees

The pandemic shone a bright light on the resilience of Canada’s healthcare system, and on the...
Event and Webinar

Canadian drug landscape update: Spring 2021 webinar

With new COVID treatments on the horizon, a growing number of biosimilar options available, and...
Report

Insights into the cost-effectiveness for cell and gene therapies

“Cell and gene therapies are some of the most exciting frontiers in modern medicine and have the...
Article

Humanizing the future of work

The past 15 months have seen a dizzying combination of accelerating, disrupted and new trends in...
Article

Estimating the financial impact of new medications for private drug plans

TELUS provides guidance on how to make a Budget Impact Analysis more relevant for private payers....
Article

2021 TELUS Health Drug Data Trends & National Benchmarks report

While COVID-19 clearly affected claims patterns for private drug plans in 2020, its net impact was,...
Article

British Columbia’s biosimilars policy a turning point for private plans

B.C.’s Biosimilars Initiative has had a profound impact on private drug plans. By the end of 2020,...
Article

Top 10 things plan sponsors need to know about depression

“There’s always a path ahead, no matter how severe your mental illness is,” said Chief Neuroscience...
Article

What you need to know about trends in medication use

The top three drug categories by eligible cost—for inflammatory disease, diabetes and skin...
Article

4 ways to prepare for the disability deluge

Within weeks of the coronavirus pandemic taking hold in Canada, plan sponsors, administrators and...
Event and Webinar

TELUS Health Annual Conference 2021

Presentations from April 20 & 27, 2021: Retrospective 2020: Data trends and national benchmarks
Event and Webinar

What to expect from Canada’s drug pipeline in 2021

Out of more than 150 drug submissions currently before Health Canada, the TELUS Health 2021 Drug...
Report

2021 category watch: The impact of new drugs

In its 2021 Category Watch: The Impact of New Drugs report, TELUS Health takes a closer look at the...
Article

What plan sponsors can learn from The Globe and Mail’s Drug Shortages Summit

On February 17, 2021, The Globe and Mail hosted an online summit to explore the impact of drug...
Article

Mental health in organizations: How are people doing?

There’s no question it’s been a stressful year, full of challenges to mental health. So, what can...
Article

Are you prepared for the coming deluge of disability claims?

Despite some supply chain challenges, vaccination plans are coming together across Canada, and...
Article

Technology is set to transform mental health treatment

Can artificial intelligence (AI) provide accurate mental health diagnoses? Can virtual reality (VR)...
Article

Optimizing wellness programs with a data-driven approach

Employers provide wellness programs as an investment in their workforce. And a happy, healthy...
Article

Pharmacogenomic testing gains foothold in group insurance

Coverage of pharmacogenomic (PGx) testing is well underway in Canada. TELUS Health has contacted 10...
Article

Private payer perspective matters when considering drug cost-effectiveness

Incremental Cost-effectiveness ratios (ICERs) – which give payers an idea about the...
Article

Market access for biosimilars in Canada still below OECD average

TELUS Health Annual Conference – The rate of penetration of biosimilar drugs in the Canadian market...
Article

Getting down to the business of health

Plan sponsors are increasingly seeing the strong value equation that connects a healthy workforce...
Article

What private plans can expect from Canada’s drug pipeline

Canada may see its first gene therapy by the end of this year. The treatment is for a very rare eye...
Article

Pharmacoeconomics: Evidence-informed drug reimbursement

A new drug may not seem affordable at face value, but is it cost-effective? Will it increase...